Antibiotic Accountability: How Countries and Companies Perform

FT dashboard tracks responses to the growing threat of antimicrobial resistance

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections, according to a new analysis. The data — mapped by the FT from work led by a team at the University of Oxford and published in Lancet Planetary Health — estimates antibiotic consumption for 204 countries between 2000 and 2018. It shows a 46 per cent increase in global antibiotic usage, with a surge in nations including Sudan, India and Vietnam.

While many poorer countries have inadequate access to antibiotics, leading to unnecessary deaths through lack of adequate treatments, other middle and higher income countries are using volumes far beyond global norms. The study, based on a combination of prescription data and statistical modelling, shows that the highest rate of consumption in a single country — measured as a defined daily dose per 1,000 people per day — is in Greece, at nearly 45.9, compared with a global average of 14.3 and an average of 21.1 in Western Europe. There has also been a sharp rise in the Middle East, where antibiotics are often provided without prescriptions, which risks the development of bacterial strains resistant to drugs. These figures are included in an FT data dashboard designed to track the emerging trends in the “silent pandemic” of antimicrobial resistance, which causes hundreds of thousands of annual deaths. The dashboard aims to plot the growth in disease, medicine usage and efforts to respond by companies, governments and others. The Center for Disease Dynamics, Economics & Policy has also attempted to calculate the extent of antibiotic usage, and fresh studies are under way to link consumption to overall estimates of the burden of antimicrobial resistance.

Compared with the funding and level of research and development activity devoted to other disease categories, such as cancer, the pipeline is thin for new antibiotics, for diagnostics to help their targeted use, and for vaccines to prevent infection.

An annual benchmarking conducted by the Access to Medicine Foundation highlights variable efforts by both innovative and generic pharmaceutical companies in a range of activities — including research, surveillance and manufacturing — to tackle antimicrobial resistance.

An analysis by Farm Animal Investment Risk & Return — a think-tank designed in part to mobilise activist investors to reduce the extent of antibiotics in animals — highlights the variable response of the agro-food and restaurant sector.

Governments and other funders have stepped up support into research around the topic, but with a wide range of different approaches and levels of commitment, as illustrated by the Global AMR R&d Hub.

Broader efforts by countries to improve stewardship, through measures such as improved diagnosis and infection control, are also highly variable, as measured by the Global Coalition on Aging’s Global AMR Preparedness Index.

Source: Financial Times

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Brazil Must Fight Antibiotic Resistance

The threat posed by antimicrobial resistance is urgent and spares no country - including Brazil. According to The Lancet, 63 deaths per 100,000 are associated with AMR in Brazil and Paraguay, a rate that exceeds the average for Latin America and the Caribbean. AMR-associated deaths in Brazil are second only to cardiovascular diseases and cancers.

We Missed 100 Million Adult Vaccines – Here’s How We Get Back on Track

Like other pandemics throughout human history, COVID-19 has caused profound changes that are still rippling through our societies, even as people are understandably eager to move on. In fact, these impacts are all the more dangerous when they are largely ignored or effectively invisible. The decline in adult vaccination may be one of the most significant, as a new report finds that ~100 million doses were missed in 2021 and 2022 alone – reversing global progress towards widespread adult immunisation as a new standard of care in a world of more old than young.

New Analysis Shows Lost Ground on Adult Immunisation During the Pandemic with 100 Million Doses Potentially Missed

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic.

Going Beyond Applause: The Potential of Caregiving to Unlock Job Opportunities of the Future

Early in the COVID-19 pandemic, the role of caregivers – staff and family who provide care for older and dependent people to carry out activities such as eating or moving - catapulted to the front of our collective conscience. The daily applause for front-line care workers showed a high level of recognition for their incredible work and provided insight into how our health systems must change as our society ages. We need to continue to recognise caregivers as essential to our ageing society.

High-Level Forum on the Silver Economy 2023

Join us for the High-Level Forum on the Silver Economy 2023. Now in its fourth year, the Silver Economy Forum 2023, December 6 and 7, will explore aging at every stage of life, looking at the growing global Silver Economy through a multigenerational lens. Linking to the goals and aspirations of the UN Decade of Healthy Ageing, SEF 2023 will highlight key themes at the intersection of aging at every age, and the Silver Economy.

Global Coalition on Aging Workshop Calls on G7 Countries to Fund Pull Incentives to Spur Antibiotic Innovation

The Global Coalition on Aging, in partnership with JPMA, today announced the release of its workshop report on the AMR crisis facing G7 countries and the world, “The Value of Pull Incentives in Japan to Encourage Investment in Antibiotic Innovation to Solve the AMR Crisis.” If strong action is not taken to address AMR, we will lose the antibiotics we need to cure infections, which is likely to outpace cancer as a major cause of death, killing an estimated 10 million by 2050.